| Dr Ryan C Cmejrek, MD | |
|
99 E 86th Ave, Ste A, Merrillville, IN 46410-6381 | |
| (219) 738-2617 | |
| (219) 769-5830 |
| Full Name | Dr Ryan C Cmejrek |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 24 Years |
| Location | 99 E 86th Ave, Merrillville, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710986765 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Community Hospital | Munster, IN | Hospital |
| Franciscan Health Crown Point | Crown point, IN | Hospital |
| St Mary Medical Center Inc | Hobart, IN | Hospital |
| Methodist Hospitals Inc | Gary, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Otolaryngology Associates Of Northwest Indiana Llc | 0547656704 | 7 |
| Carepointe, P.c. | 6608812003 | 7 |
News Archive
ImmunoCellular Therapeutics announced today that the U.S. Food and Drug Administration has granted orphan drug designation for ICT-107, the company's dendritic cell-based cancer vaccine candidate which targets glioblastoma multiforme. As a result of the orphan drug status, ImmunoCellular will be eligible to receive a number of benefits, including access to grant funding for clinical trials, tax credits, accelerated FDA approval and allowance for marketing exclusivity after drug approval for a period of up to seven years.
Scientists seeking to harness the power of the immune system to eradicate brain tumors face two major hurdles: recruiting key immune cells called dendritic cells into areas of the brain where they are not naturally found and helping them recognize tumor cells as targets for attack.
We all know the feeling of a mobile phone vibrating in our hands when announcing an incoming call. If we perceive these vibrations so clearly, it is due to specialized receptors that transduce them into neural signals sent to our brain.
Federal researchers have discovered that severe stress or trauma early in life could actually change how the brain responds to stress hormones, essentially "re-wiring" the brain for later neuropathological disorders, according to a study, "A role for corticotrophin releasing factor signaling in the lateral habenula and its modulation by early life stress," published in Science Signaling, March 6.
› Verified 8 days ago
| Entity Name | Carepointe, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023031911 PECOS PAC ID: 6608812003 Enrollment ID: O20050707000710 |
News Archive
ImmunoCellular Therapeutics announced today that the U.S. Food and Drug Administration has granted orphan drug designation for ICT-107, the company's dendritic cell-based cancer vaccine candidate which targets glioblastoma multiforme. As a result of the orphan drug status, ImmunoCellular will be eligible to receive a number of benefits, including access to grant funding for clinical trials, tax credits, accelerated FDA approval and allowance for marketing exclusivity after drug approval for a period of up to seven years.
Scientists seeking to harness the power of the immune system to eradicate brain tumors face two major hurdles: recruiting key immune cells called dendritic cells into areas of the brain where they are not naturally found and helping them recognize tumor cells as targets for attack.
We all know the feeling of a mobile phone vibrating in our hands when announcing an incoming call. If we perceive these vibrations so clearly, it is due to specialized receptors that transduce them into neural signals sent to our brain.
Federal researchers have discovered that severe stress or trauma early in life could actually change how the brain responds to stress hormones, essentially "re-wiring" the brain for later neuropathological disorders, according to a study, "A role for corticotrophin releasing factor signaling in the lateral habenula and its modulation by early life stress," published in Science Signaling, March 6.
› Verified 8 days ago
| Entity Name | Otolaryngology Associates Of Northwest Indiana Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124782842 PECOS PAC ID: 0547656704 Enrollment ID: O20220415000906 |
News Archive
ImmunoCellular Therapeutics announced today that the U.S. Food and Drug Administration has granted orphan drug designation for ICT-107, the company's dendritic cell-based cancer vaccine candidate which targets glioblastoma multiforme. As a result of the orphan drug status, ImmunoCellular will be eligible to receive a number of benefits, including access to grant funding for clinical trials, tax credits, accelerated FDA approval and allowance for marketing exclusivity after drug approval for a period of up to seven years.
Scientists seeking to harness the power of the immune system to eradicate brain tumors face two major hurdles: recruiting key immune cells called dendritic cells into areas of the brain where they are not naturally found and helping them recognize tumor cells as targets for attack.
We all know the feeling of a mobile phone vibrating in our hands when announcing an incoming call. If we perceive these vibrations so clearly, it is due to specialized receptors that transduce them into neural signals sent to our brain.
Federal researchers have discovered that severe stress or trauma early in life could actually change how the brain responds to stress hormones, essentially "re-wiring" the brain for later neuropathological disorders, according to a study, "A role for corticotrophin releasing factor signaling in the lateral habenula and its modulation by early life stress," published in Science Signaling, March 6.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ryan C Cmejrek, MD 99 E 86th Ave, Ste A, Merrillville, IN 46410-6381 Ph: (219) 738-2617 | Dr Ryan C Cmejrek, MD 99 E 86th Ave, Ste A, Merrillville, IN 46410-6381 Ph: (219) 738-2617 |
News Archive
ImmunoCellular Therapeutics announced today that the U.S. Food and Drug Administration has granted orphan drug designation for ICT-107, the company's dendritic cell-based cancer vaccine candidate which targets glioblastoma multiforme. As a result of the orphan drug status, ImmunoCellular will be eligible to receive a number of benefits, including access to grant funding for clinical trials, tax credits, accelerated FDA approval and allowance for marketing exclusivity after drug approval for a period of up to seven years.
Scientists seeking to harness the power of the immune system to eradicate brain tumors face two major hurdles: recruiting key immune cells called dendritic cells into areas of the brain where they are not naturally found and helping them recognize tumor cells as targets for attack.
We all know the feeling of a mobile phone vibrating in our hands when announcing an incoming call. If we perceive these vibrations so clearly, it is due to specialized receptors that transduce them into neural signals sent to our brain.
Federal researchers have discovered that severe stress or trauma early in life could actually change how the brain responds to stress hormones, essentially "re-wiring" the brain for later neuropathological disorders, according to a study, "A role for corticotrophin releasing factor signaling in the lateral habenula and its modulation by early life stress," published in Science Signaling, March 6.
› Verified 8 days ago
Dr. Dennis P Han, M.D Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 99 E 86th Ave, Ste A, Merrillville, IN 46410 Phone: 219-738-2617 Fax: 219-738-2145 | |
Thomas T Tarin, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 99 E 86th Ave, Suite A, Merrillville, IN 46410 Phone: 219-738-2617 Fax: 219-738-2145 | |
Dr. James Jones, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 255 E 90th Drive, Merrillville, IN 46410 Phone: 219-756-3988 Fax: 219-756-2595 |